Innovative Medication Shows Promise in Managing Resistant Hypertension and Protecting Kidney Function
A new drug, baxdrostat, shows promise in effectively lowering resistant high blood pressure and protecting kidney health, offering hope for a significant advancement in hypertension and kidney disease treatment.
A groundbreaking medication, baxdrostat, has demonstrated significant potential in lowering blood pressure levels that are difficult to control with standard treatments and may also slow the progression of kidney disease. In a recent stage 2 clinical trial involving nearly 200 participants, baxdrostat not only led to a substantial reduction in blood pressure but also showed promising effects on kidney health. Participants treated with baxdrostat exhibited less than half the amount of urinary albumin—a key marker of kidney damage—compared to those receiving traditional care, indicating healthier kidneys.
The research, led by Dr. Jamie Dwyer at the University of Utah Health, highlights the dual benefits of the drug. On average, baxdrostat lowered blood pressure by approximately 8.1 mm Hg more than standard treatments. This is corroborated by a larger, almost 800-patient trial where similar blood pressure reductions were observed, establishing baxdrostat as a potential game-changer in hypertension management.
Unlike conventional medications, baxdrostat operates through a unique mechanism by reducing the production of aldosterone, a hormone that raises blood pressure by increasing salt retention and contributes to kidney inflammation and scarring. Up to a quarter of people with resistant high blood pressure have elevated aldosterone levels, making baxdrostat particularly effective for this demographic.
Given its ability to target the hormone source directly, baxdrostat offers hope not only for better blood pressure control but also for protecting kidney function, especially for the one in seven adults in the U.S. living with chronic kidney disease. Currently, phase III trials are underway to further verify its benefits. The promising results suggest that baxdrostat could revolutionize treatment strategies for resistant hypertension and kidney health, potentially transforming patient outcomes.
Source: https://medicalxpress.com/news/2025-09-drug-lowers-treatment-resistant-high.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Patients Choosing Extended 10-Year Hormone Therapy for Breast Cancer
A recent study reveals that nearly half of women with early-stage breast cancer are opting for extended 10-year hormone therapy to reduce recurrence risk, especially among higher-risk groups. The decision is influenced by doctor recommendations and personal concerns about cancer recurrence, highlighting the importance of shared decision-making in personalized cancer treatment.
Prolactin's Role in Regulating Body Temperature During Pregnancy
New research reveals how prolactin, a key pregnancy hormone, helps regulate body temperature, ensuring maternal and fetal health during pregnancy. Discover the science behind this vital function.
Potential Impact of Republican Medicaid Reductions on Rural Hospitals
Proposed Medicaid funding cuts by House Republicans could lead to widespread closures of rural hospitals and threaten essential healthcare services for vulnerable populations across the U.S.
Many People Unaware That Knee and Groin Pain May Signal Hip Issues
A survey reveals that most Americans are unaware that knee, groin, or thigh pain can be signs of hip problems, emphasizing the need for better awareness and early diagnosis.